All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
EquityABBs-Block Trades

Pre-IPO shareholders sell 9.3% of Cosmo Pharmaceuticals

Cosmo_drugs_PA_230x150

Shares in Cosmo Pharmaceuticals, the Swiss pharmaceutical company focused on gastrointestinal and skin disorders, fell 6.4% on Friday after a group of pre-IPO shareholders sold 9.3% of the company for Sfr216m through an accelerated bookbuild led by Berenberg.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree